Every weight-loss medication I've covered on this site so far — semaglutide, tirzepatide, retatrutide — works through variations on the same basic biological system: receptors related to GLP-1, the incretin hormone released after eating. Retatrutide pushes this furthest, hitting three receptors in that same broad hormone family at once. Petrelintide, a drug that just published its full Phase 2 results, works through something genuinely different: amylin, a separate hormone system entirely. I think this distinction deserves real emphasis, because it's a concrete illustration of something I've said before on this site — there isn't one pathway governing weight regulation, and that matters for how treatment actually develops over time.
What makes amylin a different pathway
Amylin is a hormone your pancreas naturally co-secretes alongside insulin, and it acts through its own distinct receptor system — not an extension of the GLP-1 family, but a separate signaling route that also influences appetite and satiety. Petrelintide, developed by the Danish biotech Zealand Pharma, is a synthetic amylin analog designed to activate this pathway directly. The practical significance of this is real: a genuinely different mechanism means a genuinely different side-effect profile and a genuinely different opportunity to combine it with existing treatments rather than simply competing with them.
The trial data
The ZUPREME-1 Phase 2 trial, led by Dr. W. Timothy Garvey and published in The Lancet Diabetes & Endocrinology, enrolled 485 adults with obesity or overweight, without diabetes, randomized across five weekly doses of petrelintide against placebo, alongside standard diet and exercise guidance. Weight loss ranged from 7.9% to 9.8% at 28 weeks across doses, reaching as high as 10.7% at 42 weeks in the 5 mg group, compared to 1.7% with placebo.
The tolerability profile is where this drug genuinely distinguishes itself. Serious adverse events occurred in 3% of the treatment group versus 4% with placebo — essentially comparable, with no relationship to dose. Nausea was elevated compared to placebo, 20% versus 6%, but Garvey himself described this as less than half the rate typically seen in GLP-1 trials. Vomiting and diarrhea rates were similar to, or even lower than, placebo.
An important caveat about the comparisons being made
I want to flag something directly, because it's exactly the kind of claim that benefits from scrutiny. The headlines describing petrelintide as having "fewer side effects than Wegovy or Mounjaro" are based on comparing separate trials, not a head-to-head study — petrelintide was never tested directly against either drug. An independent researcher not involved in the trial made this point clearly: the data shows petrelintide works compared to placebo, but it cannot establish that it's genuinely better tolerated than specific competing drugs, since those drugs were never part of this study. The efficacy comparison carries the same limitation — petrelintide's roughly 10% weight loss trails the headline figures reported in semaglutide and tirzepatide's own separate trials, but without a direct comparison, exactly how meaningful that gap is remains genuinely uncertain.
Why the different pathway might matter beyond tolerability
This is where I think the "different pathway" framing becomes more than an academic distinction. Early preclinical research suggests petrelintide may work better specifically in combination with semaglutide, rather than simply as an alternative to it — which makes mechanistic sense if the two drugs are acting through genuinely separate systems rather than competing for the same biological target. A second trial combining petrelintide with another Zealand compound is already planned. This is the same underlying logic behind the dual-therapy approach I've described elsewhere on this site with surgery and GLP-1 therapy together — when two interventions work through different mechanisms, combining them can offer something neither achieves alone, rather than just picking the stronger of two competing options.
Where this stands right now
Petrelintide remains firmly in Phase 2. A global Phase 3 registrational program is just beginning, expected to start by the end of 2026, with no approval timeline announced. Worth noting for transparency: Zealand Pharma sponsored this trial, and reporting indicates the lead investigator has disclosed relationships with several other pharmaceutical companies as well — standard practice in this kind of research, but worth knowing directly.
What I'd want you to take from this
I think the real headline here isn't "a weaker alternative to existing GLP-1 drugs." It's that weight regulation in the body runs through more than one biological system, and treatment is beginning to reflect that directly — not just by combining surgery with medication, as I've written about elsewhere, but potentially by combining medications that work through genuinely separate pathways within the body's own hormonal signaling. That's a meaningfully different, and more interesting, story than simply ranking drugs by how much weight they produce in their own separate trials.
Curious how emerging treatments like this might fit into your own care?
No spam. Occasional new posts and updates from The Center for Metabolic Health.
Medical disclaimer: This content is provided for general educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition, and it does not create a physician-patient relationship. Every patient's medical history, health status, and treatment needs are different. Always consult your own physician or qualified healthcare provider before starting, stopping, or changing any medication or treatment, and before making any decisions based on information found here. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.